Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9315312 | 0.84 | L3MBTL1 (0.45) | L3MBTL1KDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL18697309 | 0.77 | L3MBTL1 (0.42) | L3MBTL1KDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8665021 | 0.74 | KMT2A (0.39) | L3MBTL1KDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24549924 | 0.74 | PPARG (0.44) | L3MBTL1KDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4530562 | 0.73 | RAB9A (0.35) | KMT2AALDH1A1SMN1; SMN2TDP1MAPT | |
| SCHEMBL9173326 | 0.73 | KDM4E (0.33) | KDM4E | |
| SCHEMBL15003833 | 0.73 | ESR1 (0.35) | L3MBTL1TDP1NPC1ACHE | |
| SCHEMBL9909122 | 0.73 | LMNA (0.52) | KDM4EKMT2AALDH1A1TDP1ACHE | |
| SCHEMBL6633903 | 0.72 | KMT2A (0.37) | L3MBTL1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8637379 | 0.71 | KMT2A (0.42) | L3MBTL1KDM4EKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600858-B2 | Ion selective membranes for organic electrochemical processes | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20230099030-A1 | ION SELECTIVE MEMBRANES FOR ORGANIC ELECTROCHEMICAL PROCESSES | NATIONAL SCIENCE FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| WO-2021188977-A1 | ION SELECTIVE MEMBRANES FOR ORGANIC ELECTROCHEMICAL PROCESSES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600858-B2 | Ion selective membranes for organic electrochemical processes | PHOSPHO1, SLC6A12, VDAC3 | L3MBTL1 2679/4885KDM4E 1581/4885KMT2A 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.